WebJul 9, 2024 · SGLT2 inhibitors are a group of oral medications, whereas GLP-1 receptor … WebDec 2, 2015 · Choosing an SGLT2 inhibitor with cardiovascular benefit The evidence …
GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to …
WebMar 2, 2024 · With careful monitoring, GLP-1 receptor agonists can be given to patients with a low glomerular filtration rate (GFR) (< 30 mL/min), including end-stage renal disease, whereas the SGLT2 inhibitors should not be administered … WebOct 12, 2024 · Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors can reduce CV risk in patients with T2D, and both are recommended by the American Diabetes Association to reduce the risk of major cardiovascular events (MACE). evangelion show
Key Considerations in use of SGLT2 Inhibitors and GLP-1RAs …
WebSodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Canagliflozin (Invokana) 0.77-1.03 Neutral Loss Urogenital inf. Caution if eGFR < 45 Neutral Neutral Neutral or? risk ? bone loss Hypotension Maintain adequate hydration DKA warning Post prandial Kidney 375 Dapagliflozin (Farxiga) 0.77-1.03 Neutral Loss Urogenital inf. Caution if eGFR < 60 WebPatients who have a lower cardiovascular risk should consider SGLT-2 inhibitors or GLP-1 agonists based on other established benefits such as weight control (moderate net weight loss for GLP-1... WebJan 20, 2024 · Choosing between SGLT-2 Inhibitors and GLP-1 Agonists as preferred … evangelion shinji breakdown